Search Results for "ATTRv"

Alnylam is committed to providing the healthcare community with balanced, accurate, and high-quality information about our science, therapeutic areas, and products.

More than one search term is recommended to yield the most relevant results. By searching, you confirm that your query is unsolicited.

For more information about our FDA-approved therapies, please see the Full Prescribing Information:

Evaluation of Disease Progression in Patients with ATTR Amyloidosis with Cardiomyopathy Following Treatment with Patisiran: Post hoc Analysis of the APOLLO-B Study

HELIOS-A: 9-Month Results from the Randomized Treatment Extension Period of Vutrisiran in Patients with Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy

Primary Results from APOLLO-B Open-label Extension Study of Patisiran in Patients with Transthyretin Cardiac Amyloidosis

Patisiran Treatment for ATTR Cardiac Amyloidosis: 18-Month Results of the Phase 3 APOLLO-B Study

Impact of Patisiran on Health Status and Quality of Life in Patients with Transthyretin Cardiac Amyloidosis

HELIOS-A: 18 Month Exploratory Cardiac Results from the Phase 3 Study of Vutrisiran in Patients with Hereditary Transthyretin Mediated Amyloidosis

Effect of Patisiran Treatment in Patients with hATTR Amyloidosis with Cardiomyopathy and Polyneuropathy: Post-hoc Analysis of the APOLLO-B Study

APOLLO-B, a Study of Patisiran in Patients with Transthyretin Cardiac Amyloidosis: Primary Long-term Results from the Open-label Extension Period

Patisiran Global Open-Label Extension Study at 36 Months: Effect of Long-Term Treatment on Mortality and Ambulatory Function in Patients with hATTR Amyloidosis with Polyneuropathy

Comparison of Efficacy Outcomes with Vutrisiran vs. Patisiran in hATTR Amyloidosis with Polyneuropathy: Post-hoc Analysis of the HELIOS-A Study

Effect of Patisiran on Polyneuropathy and Cardiomyopathy in Patients with Hereditary Transthyretin Mediated (hATTR) Amyloidosis with a V122I or T60A Variant: A Phase 4 Observational Study

HELIOS A: Study of Vutrisiran in Patients with hATTR Amyloidosis

NfL as a Biomarker in hATTR Amyloidosis Infographic.

Infographic companion to the article by Sato et al, "Neurofilament light chain as a biomarker for monitoring response to change in treatment in hereditary ATTR amyloidosis", published in the journal Amyloid, 2023.

Musculoskeletal Manifestations Associated with ATTR Amyloidosis

This slide deck provides disease education on ATTR amyloidosis, focusing on the musculoskeletal manifestations associated with the disease and their importance for early diagnosis and patient care.

ATTR-CM HELIOS-B Data Summary

ATTR-CM HELIOS-B Data Summary deck provides a comprehensive overview of the HELIOS-B results. Also includes information on ATTR-CM and the MOA of RNAi therapeutics.

Patisiran RWE in hATTR Amyloidosis

External title: Patisiran RWE in hATTR Amyloidosis External description: This slide deck highlights real-world evidence (RWE) data on the use of patisiran in patients with hATTR amyloidosis, including patients with polyneuropathy, cardiomyopathy, solid organ transplant, concomitant treatment or treatment switch.

For further information regarding your request, please connect with us by reaching out to your local Medical Science Liaison or contacting our Medical Information team.

Search Results for "ATTRv"

NfL as a Biomarker in hATTR Amyloidosis Infographic. Infographic companion to the article by Sato et al, "Neurofilament light chain as a biomarker for monitoring response to change in treatment in hereditary ATTR amyloidosis", published in the journal Amyloid, 2023.

Musculoskeletal Manifestations Associated with ATTR Amyloidosis This slide deck provides disease education on ATTR amyloidosis, focusing on the musculoskeletal manifestations associated with the disease and their importance for early diagnosis and patient care.

ATTR-CM HELIOS-B Data Summary ATTR-CM HELIOS-B Data Summary deck provides a comprehensive overview of the HELIOS-B results. Also includes information on ATTR-CM and the MOA of RNAi therapeutics.

NfL as a Biomarker in hATTR Amyloidosis Infographic.

Infographic companion to the article by Sato et al, "Neurofilament light chain as a biomarker for monitoring response to change in treatment in hereditary ATTR amyloidosis", published in the journal Amyloid, 2023.

Musculoskeletal Manifestations Associated with ATTR Amyloidosis

This slide deck provides disease education on ATTR amyloidosis, focusing on the musculoskeletal manifestations associated with the disease and their importance for early diagnosis and patient care.

ATTR-CM HELIOS-B Data Summary

ATTR-CM HELIOS-B Data Summary deck provides a comprehensive overview of the HELIOS-B results. Also includes information on ATTR-CM and the MOA of RNAi therapeutics.